Loading...
XSHG
688085
, Last price  
Name

Shanghai Sanyou Medical Co Ltd

Chart & performance

D1W1MN
XSHG:688085 chart
P/E
—
P/S
—
EPS
0.28
Vol. 1Y
—
Shs. 5Y
4.04%
Rev. 5Y
6.81%
Div Yld LY
—
Div Yld TTM
—
Revenues
543m
+19.66%
75,286,130139,969,162222,312,864354,319,329390,432,505593,359,315649,152,314460,392,060453,595,346542,792,500
Net income
63m
+451.85%
3,129,6315,202,06962,137,43497,818,388118,558,793186,369,948190,818,29595,582,88411,468,62163,289,500
CFO
70m
+542.40%
19,387,60921,537,48719,787,76561,721,48977,520,904144,921,298155,972,694267,433,84510,964,66670,437,228
Dividend
Jun 11, 20260.0211 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Headquartered in Shanghai, China, Shanghai Sanyou Medical Co., Ltd. focuses on the entire lifecycle of orthopedic implants, from their initial research and development through manufacturing and ultimately sales within the Chinese market. The company distributes its medical devices under the Tytus and Sanyou brand names, primarily specializing in spinal and trauma-related implants. Its spinal product line features a broad selection, including anterior cervical plates, anterior and posterior thoracolumbar systems, posterior cervical solutions, and z-minimally invasive products. For trauma injuries, Sanyou Medical offers implant systems designed for various anatomical regions, such as the shoulder and elbow, hip and pelvis, knee, and palm and wrist.

Key people

Mingyan Liu
Chairman of the Board
IPO date
Apr 09, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT